Mass spectrometry (MS)-based proteomics is emerging as a broadly effective means for
identification, characterization, and quantification of proteins that are integral components of …

Introduction Biological fluids are routine samples for diagnostic testing and monitoring.
Blood samples are typically measured because of their moderate invasive collection and …

A biomarker of synapse loss, an early event in Alzheimer's disease (AD) pathophysiology
that precedes neuronal death and symptom onset, would be a much-needed prognostic …

The glial environment influences neurological disease progression, yet much of our
knowledge still relies on preclinical animal studies, especially regarding astrocyte …

Biosensors are being developed to provide rapid, quantitative, diagnostic information to
clinicians in order to help guide patient treatment, without the need for centralised laboratory …

Abstract Analysis of extracellular vesicles (EVs) derived from plasma or cerebrospinal fluid
(CSF) has emerged as a promising biomarker platform for therapeutic monitoring in …

Introduction Biomarkers monitoring synaptic degeneration/loss would be valuable for
Alzheimer's disease (AD) diagnosis. Postsynaptic protein neurogranin may be a promising …

Human follicular fluid is a complex body fluid that constitutes the microenvironment of
develo** follicles in the ovary. Follicular fluid contains a number of proteins that modulate …

Puromycin is a tyrosyl-tRNA mimic that blocks translation by labeling and releasing
elongating polypeptide chains from translating ribosomes. Puromycin has been used in …

Amyotrophic lateral sclerosis (ALS) is a highly heterogeneous disease with no effective
treatment. Drug development has been hampered by the lack of biomarkers that aid in early …